Compare Lamb Weston Holdings Inc (LW) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Lamb Weston Holdings Inc trades at $46.9 (market cap $6.43B), while Regeneron Pharmaceuticals Inc trades at $671.56 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 11× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays the higher dividend (3.26%). Which is the better fit depends on your goals.
| LW | REGN | |
|---|---|---|
Market Cap | $6.43B | $70.47B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $812.27 |
52-Week Low | $38.48 | $545.46 |
Enterprise Value | $10.40B | $64.42B |
Dividend Yield | 3.26% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $46.59, down 0.43% today, with a bullish technical signal from moving averages and a consensus analyst price target of $49.33. The company reported revenue of $6.45B in 2025 and has beaten EPS estimates in the last three quarters. Recent news highlights its 'Focus to Win' strategy showing traction, with volume gains in North America and cost-saving initiatives supporting its turnaround.
The outlook remains cautiously optimistic, with potential upside from continued earnings beats and strategic execution, but risks include a pending class-action lawsuit, margin pressures, and high debt levels. Analyst sentiment is mixed, with 35% buy ratings, reflecting confidence in the turnaround amid operational challenges.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
